Pipeline: Stenoparib (2X-121)

Stenoparib — A Dual PARP and Tankyrase Inhibitor

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP®.

The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.

The U.S. FDA has approved an Investigational Device Exemption (IDE) for use of the Stenoparib DRP® as a companion diagnostic in the clinical trial.

Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

 

Stenoparib is also being evaluated in early stage studies for its activity against COVID-19.

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.

Allarity Therapeutics Logo